David Buckeridge was elected as Chair of the NIAB Board in June 2023.
Dr Buckeridge has 35 years of operational management experience in the life science and agribusiness industries. With a PhD in genetics and plant sciences from the University of Wales, David began his career with AstraZeneca, spending 20 years in a variety of management positions globally. After serving as Group CEO of Advanta BV, the largest independent agronomic seed business in the world at that time, David led its exit from private equity ownership and advised on its successful initial public offering to the Indian stock market in 2007. Subsequently, he has played a senior advisory role to both strategic and financial investors in the life sciences and agribusiness, focusing on the operational and strategic planning aspects of these industries. He has served as director and chair of a range of companies in the agribusiness, pharma and public health industries, and is currently Chair of the Board of Protealis and of Cycle Pharmaceuticals and an independent director of Velcourt Ltd.